This inventor holds 24 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Therapeutic Compounds. Top assignees: Xenon Pharmaceuticals Inc., Genentech, Inc., Zalicus Pharmaceuticals, Ltd.. Active years: 2015-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Burnaby, CA (2015 - 2021)
- Vancouver, CA (2015 - 2023)
Company Filing History:
23 out of 110 
14 out of 3,302 
1 out of 8 Years Active: 2015-2023
Areas of Expertise:
Title: The Innovative Contributions of Michael Edward Grimwood
Introduction: Michael Edward Grimwood is a prominent figure in the field of medicinal chemistry, known for his significant contributions to the development of therapeutic agents. Based in Burnaby, Canada, he holds an impressive portfolio of 24 patents that highlight his dedication to advancing medical science.
Latest Patents: Among his most recent innovations are two notable patents concerning benzenesulfonamide compounds. The first patent, "Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents," focuses on compounds that target voltage-gated sodium channels, which play a crucial role in conditions such as epilepsy and epileptic seizure disorders. The second patent, "Benzenesulfonamide compounds and their use as therapeutic agents," similarly pertains to benzenesulfonamide compounds for the treatment of diseases associated with these channels, particularly focusing on epilepsy. These inventions embody his commitment to addressing important health concerns through innovative solutions.
Career Highlights: Grimwood has worked with several leading companies in the pharmaceutical industry, including Xenon Pharmaceuticals Inc. and Genentech, Inc. His roles at these organizations have allowed him to translate scientific research into impactful therapies, showcasing his expertise in drug development and innovation.
Collaborations: Throughout his career, Michael has collaborated with talented individuals such as Christoph Martin Dehnhardt and Thilo Focken. These partnerships have fostered a supportive environment for innovation, allowing them to tackle complex scientific challenges together.
Conclusion: Michael Edward Grimwood's contributions to the field of medicinal chemistry and his extensive patent portfolio reflect his status as a leader in innovation. His work not only enhances our understanding of therapeutic agents but also paves the way for new treatments for challenging medical conditions. As he continues his research, the impact of his innovations will undoubtedly resonate within the medical community and beyond.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile